Industry Relations Council
ASPHO Industry Relations Council (IRC) participation is available to those organizations that support the goals and mission of ASPHO. ASPHO's enhanced IRC program features tiered participation levels to allow companies of all sizes to participate, and includes expanded opportunities to engage with ASPHO. IRC participation offers recognition throughout the year and collaboration opportunities for improving patient care.
The ASPHO Industry Relations Council hopes to
- build positive relationships and foster dialogue
- gain greater understanding of mutual areas of interest
- further programs that benefit patients and their families.
Annual dues for participation in ASPHO's Industry Relations Council start at $7,500
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options, so they can live their lives more fully and redefine what is possible. As a leader in sleep medicine and with a growing hematology/oncology portfolio, Jazz has a diverse portfolio of products and product candidates in development, and is focused on transforming biopharmaceutical discoveries into novel medicines.
Bayer is a global Life Sciences leader in cardiopulmonology, hematology, neurology, oncology and women’s health. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives by developing innovative therapies and delivering first-in-class educational and support programs to meet their needs.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
ApoPharma, a member of the Apotex group of companies, is a pharmaceutical company devoted to the discovery, development, and provision of new medicines to help improve the quaility of life of patients with debilitating and life-threateneing diseases. Investigation into the pathological role of iron in human disease, and how to use novel medicines to treat conditions created or worsened by iron, is a major research focus of ApoPharma.
Servier Pharmaceuticals is a commercial-stage company, governed by a non-profit foundation, driven by discovery in oncology and potentially other areas of unmet medical need. Our independence allows us to be more forward thinking and make sustainable choices. We are poised to be an innovative leader serving U.S. patients and caregivers.